The Living Guidelines: UA/NSTEMI Recommendations for UA/NSTEMI in Women Polling Results for CLASS I Guidelines

Any recommendations found on these pages are for education use only. WikiDoc is not a substitute for a licensed healthcare provider. Please see the disclaimers page for important information regarding limitations of the information found here. In suggesting edits to the guidelines, WikiDoc suggests that the following classification scheme be used. Read more about the classification scheme used by the ACC / AHA Guidelines Committee here.

Class I Guidelines
1. Women with UA/NSTEMI should be managed with the same pharmacological therapy as men both in the hospital and for secondary prevention, with attention to antiplatelet and anticoagulant doses based on weight and renal function; doses of renally cleared medications should be based on estimated creatinine clearance. (Level of Evidence: B)

 UA/NSTEMI Guidelines Class I Recommendation 1 for Post discharge UA/NSTEMI in Women should be: CLASS I CLASS IIa CLASS IIb CLASS III

2. Recommended indications for noninvasive testing in women with UA/NSTEMI are similar to those for men. (Level of Evidence: B)

 UA/NSTEMI Guidelines Class I Recommendation 2 for Post discharge UA/NSTEMI in Women should be: CLASS I CLASS IIa CLASS IIb CLASS III

3. For women with high-risk features, recommendations for invasive strategy are similar to those of men (Level of Evidence: B)

 UA/NSTEMI Guidelines Class I Recommendation 3 for Post discharge UA/NSTEMI in Women should be: CLASS I CLASS IIa CLASS IIb CLASS III

4. In women with low-risk features, a conservative strategy is recommended. (Level of Evidence: B)

 UA/NSTEMI Guidelines Class I Recommendation 4 for Post discharge UA/NSTEMI in Women should be: CLASS I CLASS IIa CLASS IIb CLASS III